Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04911166 · ClinicalTrials.gov registry record · Phase 1
Phase I Trial of Atezolizumab and Interleukin-12 Gene Therapy in Metastatic Non-Small Cell Lung Cancer With Progression on First-Line Immunotherapy With or Without Chemotherapy
A Phase 1 study, sponsored by The Methodist Hospital Research Institute.
- Terminated
- Registry status
- Phase 1
- Development phase
- 13
- Enrollment target
NCT04911166 is a Phase 1 study that was terminated before completion, run by The Methodist Hospital Research Institute. The registered enrollment target is 13 participants.
The verdict
NCT04911166, a Phase 1 study, was terminated before completion, sponsored by The Methodist Hospital Research Institute.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 13 participants
- Enrollment target
Study Summary
This is a Phase I study evaluating the safety of atezolizumab in combination with ADV/IL-12 gene therapy in patients with metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on first-line immunotherapy with or without chemotherapy.
Interventions
- COMBINATION_PRODUCT Atezolizumab and Interleukin-12 Gene Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2021-10-14 |
| Est. Completion | 2025-04-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04911166
The ClinicalTrials.gov registry entry for NCT04911166 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The Methodist Hospital Research Institute, which has 126 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Atezolizumab and Interleukin-12 Gene Therapy is the first listed.
NCT04911166 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04911166 about?
NCT04911166 is a clinical study titled "Phase I Trial of Atezolizumab and Interleukin-12 Gene Therapy in Metastatic Non-Small Cell Lung Cancer With Progression on First-Line Immunotherapy With or Without Chemotherapy". This is a Phase I study evaluating the safety of atezolizumab in combination with ADV/IL-12 gene therapy in patients with metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on first-line immunotherapy with or without chemotherapy.
What is the current status of trial NCT04911166?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2021-10-14. Estimated completion is 2025-04-01.
What interventions are being tested in trial NCT04911166?
The interventions under investigation include: Atezolizumab and Interleukin-12 Gene Therapy (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT04911166?
This trial is sponsored by The Methodist Hospital Research Institute, which has 126 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.